FORM OF INCENTIVE STOCK OPTION AGREEMENTIncentive Stock Option Agreement • March 28th, 2002 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Illinois
THIS AGREEMENT is entered into and effective as of this day of , (the “Date of Grant”), by and between BioSante Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and (the “Optionee”).
ContractLicense Agreement • March 28th, 2002 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances)
[Portions of this Exhibit have been omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A copy of this Exhibit with all sections intact has been filed separately with the Securities and Exchange Commission.]
EMPLOYMENT AGREEMENTEmployment Agreement • March 28th, 2002 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Illinois
This EMPLOYMENT AGREEMENT (this “Agreement”) is made as of this 1st day of October, 2000 (the “Effective Date”), by and between BioSante Pharmaceuticals, inc. (the “Company”) and Steve J.D. Bell (“Employee”).
Second Amendment to Exclusive License Agreement for Selected Applications of Coated Nanocrystalline Particles between The Regents of the University of California and BioSante Pharmaceuticals, Inc. UC Case No 1989-204Exclusive License Agreement • March 28th, 2002 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances)
This second amendment (“Second Amendment”) is effective this 7th day of May, 2001, by and between The Regents of the University of California (“The Regents”), a California corporation, having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200, and BioSante Pharmaceuticals, Inc. (“Licensee”), a Wyoming corporation, having a principal place of business at 175 Olde Half Day Road, Suite 247, Lincolnshire, Illinois 60069.
SEPARATION AGREEMENT AND MUTUAL RELEASESSeparation Agreement • March 28th, 2002 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Illinois
THIS SEPARATION AGREEMENT (“Agreement”) is entered into effective this 1st day of February, 2002, by and between John E. Lee (“Employee”) and BioSante Pharmaceuticals, Inc. (“Employer”) (collectively referred to as the “Parties”), to resolve all issues related to or arising out of Employee’s former full-time employment with Employer and Employee’s September 28, 2001 separation. In consideration of the mutual covenants contained herein, the sufficiency of which the Parties acknowledge, the Parties agree as follows:
ContractLicense Agreement • March 28th, 2002 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Illinois
[Portions of this Exhibit have been omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A copy of this Exhibit with all sections intact has been filed separately with the Securities and Exchange Commission.]
CONSULTING AGREEMENTConsulting Agreement • March 28th, 2002 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances)
This Agreement is made and entered into this 1st day of January 2001, by and between BioSante Pharmaceuticals, Inc., a Delaware corporation, 111 Barclay Blvd., Lincolnshire, Illinois 60069 (“BioSante”) and Scientific Research Development Corporation, an Illinois corporation, 14308 W. Braemore Close, Libertyville, Illinois 60048 (“SRDC”).
ContractLicense Agreement • March 28th, 2002 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances)
[Portions of this Exhibit have been omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A copy of this Exhibit with all sections intact has been filed separately with the Securities and Exchange Commission.]
